Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06866405 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose

A Phase 3 study of RSV Infection, sponsored by Pfizer.

Recruiting
Registry status
Phase 3
Development phase
550
Enrollment target
20
Study locations

NCT06866405 is a Phase 3 study of RSV Infection that is actively recruiting participants, run by Pfizer. The registered enrollment target is 550 participants, below the 678-participant average among 8 other RSV Infection trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06866405, a Phase 3 study of RSV Infection, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 3
Development phase
550 participants
Enrollment target
20
Study locations

Study Summary

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

Conditions Studied

RSV Infection

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL RSVpreF

Study Locations (20)

California

  • Ronald Reagan UCLA Medical Center - Los Angeles
  • Ronald Reagan UCLA Medical Center (inpatient hospital) - Los Angeles
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA (outpatient clinic) - Los Angeles
  • UCLA Clinical and Translational Research Center (research clinic) - Los Angeles
  • UCLA - Los Angeles
  • Lucile Packard Children's Hospital-Labor and Delivery Unit - Palo Alto
  • Stanford Obstetrics Clinic - Palo Alto
  • Stanford University Medical Center - Palo Alto
  • Stanford University - Palo Alto

Alabama

  • Center for Research in Women's Health - Birmingham
  • Children's of Alabama - Birmingham
  • University of Alabama at Birmingham - School of Medicine - Birmingham
  • University of Alabama at Birmingham Women & Infants Center - Birmingham
  • USA Health Children's and Women's Hospital - Mobile
  • USA Health Strada Patient Care Center - Mobile

Colorado

  • Anschutz Health Sciences Building (AHSB) - Aurora
  • Children's Hospital Colorado - Aurora
  • CU Research Pharmacy - Aurora
  • University of Colorado AO1 UCH - Aurora

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2025-04-16
Est. Completion 2028-02-24
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06866405

The ClinicalTrials.gov registry entry for NCT06866405 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 678-participant average among 8 other RSV Infection trials with a reported enrollment target (19% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06866405 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT06866405 about?

NCT06866405 is a clinical study titled "A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose". This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

What is the current status of trial NCT06866405?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-04-16. Estimated completion is 2028-02-24.

What conditions does trial NCT06866405 study?

This clinical trial studies the following conditions: RSV Infection.

What interventions are being tested in trial NCT06866405?

The interventions under investigation include: Placebo (BIOLOGICAL), RSVpreF (BIOLOGICAL).

Who is sponsoring clinical trial NCT06866405?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06866405 being conducted?

This trial has 20 study locations across Alabama, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for RSV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

RSV Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.